TMCnet: Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT Yahoo Finance: Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ... Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) Self-administered intranasal etripamil was nearly twice as likely as placebo to terminate a paroxysmal supraventricular tachycardia (PSVT) episode within 30 minutes and reduced emergency department ...
Monthly Prescribing Reference: Trial Evaluating At-Home PSVT Treatment With Etripamil Nasal Spray Misses Primary End Point Trial Evaluating At-Home PSVT Treatment With Etripamil Nasal Spray Misses Primary End Point
